Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy

Author:

Schulz MartinORCID,Laufs UlrichORCID

Abstract

AbstractPrimary medication non-adherence describes the situation when a first prescription for a new medication is never filled. Primary non-adherence is an important, yet understudied aspect of reduced effectiveness of pharmacotherapy. This review summarizes the frequency, impact, reasons, predictors, and interventions regarding primary non-adherence to cardiovascular/cardiometabolic drugs. The current literature reveals a high prevalence of primary non-adherence. The individual risk of primary non-adherence is determined on multiple factors, e.g., primary non-adherence of lipid-lowering drugs is higher compared to antihypertensive medications. However, the overall rate of primary non-adherence is > 10%. Additionally, this review identifies specific areas for research to better understand why patients forgo evidence-based beneficial pharmacotherapy and to explore targeted interventions. At the same time, measures to reduce primary non-adherence—once proven to be effective—may represent an important new opportunity to reduce cardiovascular diseases.

Funder

Freie Universität Berlin

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference109 articles.

1. GBD 2017 Causes of Death Collaborators, Roth GA et al (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1736–1788. https://doi.org/10.1016/S0140-6736(18)32203-7

2. Kaski JC, Tamargo J, Savarese G (2020) Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. Eur Heart J Cardiovasc Pharmacother 6:277–279. https://doi.org/10.1093/ehjcvp/pvaa090

3. Tamargo J, Kjeldsen KP, Delpón E, Semb AG, Cerbai E, Dobrev D, Savarese G, Sulzgruber P, Rosano G, Borghi C, Wassman S, Torp-Pedersen CT, Agewall S, Drexel H, Baumgartner I, Lewis B, Ceconi C, Kaski JC, Niessner A (2022) Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 8:406–419. https://doi.org/10.1093/ehjcvp/pvac005

4. Lappe V, Dinh TS, Harder S, Brueckle M-S, Fessler J, Marschall U, Muth C, Schubert I (2022) Multimedication guidelines: assessment of the size of the target group for medication review and description of the frequency of their potential drug safety problems with routine data. Pharmacoepidemiology 1:12–25. https://doi.org/10.3390/pharma1010002

5. Joyce GF (2010) Understanding primary nonadherence. Am J Pharm Benefits 2:111–118

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3